Eli Lilly to trial use of weight loss drugs to combat unemployment in UK
The U.K. is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with weight-loss treatment giant, Eli Lilly.
Eli Lilly to invest $364M in UK trial linking obesity drug to employment
The company has committed £279 million ($364 million) to support national efforts aimed at reducing obesity, a critical health issue that also contributes to the UK’s high rates of economic inactivity.
Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock
One of the downsides of treatments such as Ozempic or Mounjaro is that even though patients wind up losing weight, they also tend to shed muscle mass. Losing too much muscle mass can be a health risk as it significantly impacts energy levels, mobility, bone strength, and more.
Britain to study use of Lilly's weight loss drug to get people back to work
Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high rate of long-term sickness that has become a major drag on the economy. Health minister Wes Streeting predicted the use of the drug - a competitor to Novo Nordisk's Ozempic - could help transform the health of the nation,
How will weight loss drug trial for unemployed work?
A study on the "real-world" effectiveness of weight loss drugs is set to measure the impact on the job prospects of people living with obesity in Greater Manchester. The five-year clinical trial was announced as part of a £279m plans by US pharmaceutical giant Eli Lilly to work with the UK government to address public health challenges like obesity.
Unemployed to be given weight-loss jab to help them back into work
The new trial aims to gather evidence of the effects of the drug tirzepatide – sold by pharmaceutical company Lily under brand name Mounjaro
UK plans weight loss drug trials to get people back to work
The UK plans to test US firm Eli Lilly' s weight loss jab Mounjaro to help the burden on the national healthcare system. Over a quarter of UK adults suffered from obesity in 2023 according to government data.
Unemployed obese people to be given weight loss jabs to help them 'get back to work'
Health Secretary Wes Streeting said "widening waistbands" were placing a burden on the NHS and Ozempic or Mounjaro could be administered
How Eli Lilly Outpaces Nvidia—Here Is One Chart
Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...
Eli Lilly: A Strong Buy on Robust Revenue Growth and Expanding Market Potential
DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating yesterday. Nico Chen has given his Buy rating due ...
Which Pharma Stock Is the Better Bargain Buy: Pfizer or Eli Lilly?
With valuations growing across the stock market and the biopharma sector, it's only natural for value-sensitive investors to ...
FiercePharma1d
In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...
bovnews1d
Eli Lilly And Co (LLY)’s Stock Surge: What You Need to Know
On Friday, Eli Lilly And Co (LLY) stock saw a modest uptick, ending the day at $932.06 which represents a slight increase of $21.37 or 2.35% from the prior close of $910.69. The stock opened at ...
With Its GLP-1 Drugs No Longer in a Shortage, Is Now the Time to Buy Eli Lilly Stock?
While artificial intelligence (AI) has been one of the hottest investing trends, GLP-1 weight loss drugs are a close second.
Eli Lilly To Invest $364 Mln In UK's Biotech Segment To Tackle Health Challenges
Eli Lilly and Co. (LLY) is planning to invest $364 million or 279 million pounds in the biotechnology segment in the U.K., to ...
Eli Lilly announces $4.5 billion research and manufacturing facility in Lebanon LEAP district
Scheduled to open in late 2027, the site will combine research and manufacturing and increase the company's investment in the ...
Analysis
Eli Lilly: Why the Stock Has Been Surging and Why It Could Retain Momentum
However, the stock market largely attributes value to a company based on its ability to generate earnings in the future. Based on Lilly’s next twelve months forward P/E ratio, investors are paying ...
Eli Lilly and Company (LLY): Growth Driven by Patents and Pipeline Milestones
Best Stocks to Invest in Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands ...